I'm almost 50, but I look 10 years younger. My secret weapon? This anti-aging eye cream that's on sale for $19
When I turned 40, with a baby on the way, it became much more challenging to conceal the puffy eyes and dark circles of a sleepless night. A few years later, I added another kiddo, and tired eyes became my trademark look.
I tried dozens of products to revive the delicate under-eye area, but it wasn't until CeraVe's Eye Repair Cream that I actually started to notice long-term improvements. As someone with easily irritated eyes, this lightweight cream is my daily go-to. So, when my four-year-old is up at 3 a.m. with an ear infection, CeraVe's eye cream will help to hide the evidence of a sleepless night.
I'm not the only one who loves this affordable beauty product — according to our data, hundreds of Yahoo readers have also snapped it up. Read on to find out why I'm obsessed — and to shop it on sale for $19.
The details
This fragrance-free, ophthalmologist-tested eye cream contains three essential ceramides and hydrating hyaluronic acid. It's made with a patented delivery system that continually releases the ingredients so your eyes stay moisturized all day long. With continued regular use, you will notice a reduction in dark circles and under-eye puffiness.
Apply a few dots of the cream to your under-eye area in the morning and evening, and gently smooth until fully absorbed. It works great alone or under makeup.
The CeraVe eye cream, developed with dermatologists, is non-comedogenic and great for all skin types.
What I like about it
It's great for sensitive eyes: I love how the CeraVe cream moisturizes without irritating my sensitive eyes. It absorbs quickly and is a great primer for my under-eye concealer. Each application requires just a few dots of the product, so the little tube goes a long way.
Dermatologist-approved: I also appreciate that the product has been recognized by the Canadian Dermatology Association and has been well-tested by experts. It's not just some gimmicky eye cream but one that has a lot of science behind it, which matters to me.
Great for hyperpigmentation: With more than 3,600 reviews and a 4.3-star rating, it's clear I am not the only one who swears by this hydrating cream. One shopper said they wished they had found it sooner as it significantly "reduced hyperpigmentation" under their eyes. They stated that their under-eye area became 30 per cent lighter, which they say is a "big win."
Not greasy: Another reviewer mentions how "non-greasy" the cream is and that it doesn't irritate sensitive eyes, while another person calls it a "wonderful product."
$19 $24 at Amazon
Other mature beauty & fashion recommendations:
I'm a 48-year-old mom who loves shopping at Amazon — 12 summer tops I'm buying, all under $50
I tried on 13 Reitmans dresses on sale for under $75 — if you're in your 40s or 50s, these styles are seriously good
These viral Amazon eye masks help make my bags look 'less puffy' — and they're on sale right now
Room for improvement
It's not a quick-fix eye cream: This product is great, but it's not a fast-acting wonder cream. You need to use it for several weeks, if not months, to see any remarkable improvements. Also, you can't skip applications, or it will set your results back. Commit to using it for a solid six months before you assess if it's working for you.
Some Amazon reviewers mentioned they saw no visible difference after a few weeks; however, from personal experience, the cream takes time to do its thing. I promise, if you stick with it, your under-eye area will improve — just don't give up!
It's not as hydrating as other eye creams: The eye cream could be a tad thicker; however, it probably wouldn't absorb as well if it was. CeraVe has a unique formula that may take a while to work, but once it does, it's great. My advice? Don't throw in the towel just yet.
What reviewers are saying
With hundreds of five-star reviews, I am far from the only fan of CeraVe's Eye Repair Cream.
One reviewer, who has struggled with "hollow eyes" and "hyperpigmentation" their "whole life," says the eye cream has made their under-eye area "about 30 per cent lighter" — a "big win" for them.
They write that their dark eye bags are "barely noticeable" after applying makeup. "I will definitely be buying [it] again."
Another shopper agrees it's a "great cream for dark circles," adding that it works "way better than expensive eye creams."
"Every dollar spent on it is worth it," they write.
"My advice," echoes a third shopper: "Throw out all your expensive skin care" and only buy CeraVe products.
They're "reasonably priced," and, importantly, "they work."
Despite thousands of five-star reviews, some warn it's "not a miracle product" and agree it can take a few months to show noticeable results.
The verdict
I love CeraVe products, and this one is no exception. It's gentle on my eye area, and after using it for a few months straight, I saw significant improvements in my dark circles and under-eye puffiness.
That said, if you are looking for something to quickly erase a night out with the girls or a long overseas flight, this is probably not going to provide the quick fix you need. This lightweight cream will yield results, but it's going to take some time. If you commit to using it twice a day for the next six months, I'm certain you will be impressed with what you see (and don't see) under your eyes in the morning.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition
On Tuesday, the eye care company Alcon Plc (NYSE:ALC) agreed to acquire STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the implantable collamer lens (ICL). The acquisition includes the EVO family of lenses (EVO ICL) for vision correction for patients with moderate to high myopia (nearsightedness), with or without astigmatism. Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, which represents approximately a 59% premium to STAAR's 90-day Volume Weighted Average Price (VWAP) and a 51% premium to the closing price of STAAR common stock on August 4, transaction represents a total equity value of approximately $1.5 billion. Alcon intends to finance the transaction by issuing short- and long-term credit facilities. The transaction is anticipated to close in approximately six to 12 months and is expected to be accretive to earnings in year two. 'With the number of high myopes rising globally, the acquisition of STAAR enhances our ability to offer a leading surgical vision correction solution for those who are not ideal candidates for other refractive surgeries such as LASIK,' said David Endicott, CEO of Alcon. An estimated 50% of the world will be myopic by 2050, and today, nearly 500 million people are considered high myopes. The EVO family of ICLs are implanted between the iris (the colored part of the eye) and the natural crystalline lens during a procedure that does not remove corneal tissue. This move follows Alcon's recent announcement in July regarding its intention to acquire LumiThera, Inc. and its Photobiomodulation (PBM) Device for dry age-related macular degeneration (AMD). Data from the LIGHTSITE I, II, and III clinical trials consistently showed that PBM treatments provide visual acuity improvement with no treatment-related serious adverse events reported. PBM received FDA de novo market authorization in November 2024 and CE Mark in November 2018. PBM is available in Europe, Latin America, Singapore, the U.K., and the U.S. The transaction does not include the acquisition of AdaptDx and Nova/Diopsys diagnostic devices, which will be separated and spun off to LumiThera's shareholders before Alcon's acquisition and will continue to be marketed and sold by the LumiThera spin-off. Alcon and LumiThera anticipate the acquisition to be completed in the third quarter of 2025. Price Action: ALC stock is trading lower by 1.17% to $86.79 premarket, and STAA stock is trading higher by 44.9% to $26.78 at last check Tuesday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? STAAR SURGICAL (STAA): Free Stock Analysis Report This article Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Digital health company eMed taps former X boss Linda Yaccarino as CEO
(Reuters) - Digital health platform eMed Population Health said on Tuesday it has appointed Linda Yaccarino, the former CEO of social media site X, as its chief executive officer. The online weight management company's digital platform provides at-home diagnostics, proctor-led screenings, physician-guided prescribing for patients with obesity and type 2 diabetes. Yaccarino, one of Elon Musk's top deputies, stepped down from her role at the social media site in July, in a surprise move just months after the platform was acquired by the billionaire's AI startup, xAI.
Yahoo
37 minutes ago
- Yahoo
Annual spending on specialty drugs continues to increase but at a slower pace than prior years, driven in part by biosimilar adoption.
DALLAS, August 05, 2025--(BUSINESS WIRE)--Pharmaceutical Strategies Group ("PSG"), an EPIC company, released the Artemetrx State of Specialty Spend and Trend report. This annual report provides a comprehensive analysis based on real world data of utilization of specialty medications across both pharmacy and medical benefits. This year's report revealed per member per year specialty drug cost increased from $1,333 in 2023 to $1,641 in 2024. However, specialty drug trend decreased to 9.6% in 2024 on a gross cost basis, a decline from 14.4% in 2023. Notably, cost per claim was meaningfully less of a contributor to trend this year versus recent years. "The data reveals a compelling story regarding what is happening with specialty drugs. Overall costs continue to increase for healthcare payers, but what is driving that cost is changing," stated Morgan Lee, PhD, Senior Director of Research & Strategy at PSG. "Adoption of Humira biosimilars helped pull specialty trend down this year, which is evident throughout the report," Lee added. While Humira continued its multi-year reign as the top specialty drug in terms of overall spend, this popular drug experienced negative utilization and cost per claim trends driven by the adoption of biosimilars. "In 2024, we saw the benefit to healthcare payers of Humira biosimilars as PBMs shifted strategies to take advantage of competition in the market," observed Renee Rayburg, RPh, Vice President of Clinical Strategy at PSG. "We expect to see faster adoption of Stelara biosimilars, which entered the market early this year. However, we're also seeing a push to move patients from these drugs to other brand drugs that do not have biosimilar competition." The Artemetrx State of Specialty Spend and Trend Report reflects PSG's commitment to providing data-driven insights regarding the management of and opportunities to optimize specialty medications. The complimentary report can be downloaded here. Additional findings covered in the report include: The percentage of members utilizing a specialty drug increased (4.7%), while average specialty claims per utilizer was steady (5.9) The shift of specialty drug spending to the pharmacy benefit continued The top three categories for specialty drug spend remained unchanged: Inflammatory Disorder, Oncology, Multiple Sclerosis PSG will host a webinar on August 13th, at 1:00 ET to discuss how this report can shape a roadmap for proactive specialty spend control. Registration is available online. About Pharmaceutical Strategies Group (PSG) Pharmaceutical Strategies Group, an EPIC company, relentlessly advocates for clients as they navigate complex and ever-changing drug cost management challenges. PSG is an independent consultant, empowering healthcare payers to optimize their pharmacy program. As a strategic partner, PSG helps clients by providing industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year. About Artemetrx® Artemetrx is a proprietary SaaS platform developed by Pharmaceutical Strategies Group, an EPIC company. As a revolutionary technology solution integrating pharmacy and medical claims data for specialty drug cost management, Artemetrx provides market-leading specialty drug insights to payers. It delivers unparalleled intelligence and line-of-sight into serious challenges perpetuating out-of-control drug costs and compromised patient outcomes. PSG's innovative drug management solutions, including Artemetrx, deliver actionable insights with exceptional financial and clinical value. PSG functions as a strategic partner through industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year. View source version on Contacts Artemetrx Business Development Travis Media Contact Gregory FCA For Pharmaceutical Strategies GroupKara Lesterepic@ Sign in to access your portfolio